Vaccination – the best method of combating serious infectious diseases
More details
Hide details
Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej Uniwersytetu Medycznego w Lublinie
Halina Szymczyk   

Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej Uniwersytetu Medycznego w Lublinie
Med Og Nauk Zdr. 2016;22(4):245–252
]Introduction and aim of the paper:
The discovery in the eighteenth century of the first vaccine created an opportunity to fight dangerous diseases at the stage of prevention. However, recent statistics indicate an increase in the number of unvaccinated people. This may result from insufficiently widely promoted information in society. The aim of this study is to present current knowledge about vaccination and vaccines available.

]Brief description of the state of knowledge:
Vaccination involves the administration of a microorganism or fragment thereof in order to stimulate the immune system to an immune response. The B cells, after contact with foreign antigen, produce specific antibodies to eliminate the microorganism. At the same time, „immunological memory cells” are formed in the body which after re-contact with a given antigen cause the rapid production of highly specific antibodies to combat infections. Vaccines contain attenuated antigens (live, free of pathogenicity) or inactivated (detoxified) and auxiliary substances increasing their efficacy and safety (adjuvants, preservatives and stabilizers). Knowledge of these substances plays an important role in qualifying for vaccination, as in people with a predisposition some of them may cause hypersensitivity reactions. Proper qualification ensures the effectiveness and safety of vaccination.

Thanks to vaccinations, we have practically avoided the outbreak of many diseases, carrying the risk of severe clinical course, serious complications and even death. Alarming statistics raise concern because the increasing percentage of unvaccinated persons greatly increases the risk of the return of a global epidemic.

Czarkowski MP, Kondej B, Staszewska-Jakubik E, Cielebąk E. Szczepienia ochronne w Polsce w 2014 roku. NIZP-PZH Warszawa, 2015.
Mrozińska M, Bernatowska E, Mik E. Skład i bezpieczeństwo szczepionek. Przew Lek. 2004; 8: 88–101.
Wysocki J, Mrukowicz J. Immunoprofilaktyka chorób zakaźnych u dorosłych. W: Gajewski P. Interna Szczeklika. Medycyna Praktyczna Kraków; 2015. p. 2400–2416.
Wysocki J, Czajka H. Szczepienia w pytaniach i odpowiedziach. Wyd. V. Helpmed Kraków, 2014.
Bernatowska E, Grzesiowski P, Mikołuć B. Szczepienia ochronne. Obo¬wiązkowe i zalecane od A do Z. PZWL, 2015.
Mrożek-Budzyn D. Wakcynologia Praktyczna. Wyd. V. α-medica Press, 2015.
Rozporządzenie Ministra Zdrowia z dn 21.12.2010 r. w sprawie niepożądanych odczynów poszczepiennych oraz kryteriów ich rozpoznawania. Dziennik Ustaw nr 254. poz. 1711.
Załącznik do komunikatu Głównego Inspektora Sanitarnego z dn. 16.10.2015 r. w sprawie Programu Szczepień Ochronnych na rok 2016. Dziennik Urzędowy Ministra Zdrowia. poz. 63 (19 października 2015).
Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG et al. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015; 64 (34): 944–947.
Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥ 65 years: recommendations of the Advisory Committee on Immunization Practi¬ces (ACIP). MMWR Morb Mortal Wkly Rep. 2014, 19; 63 (37): 822–825.
Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 Influenza Season. Am J Transplant. 2015; 15 (10): 2767–2775.
Introduction of inactivated poliovirus vaccine and switch from trivalent to bivalent oral poliovirus vaccine – Worldwide, 2013–2016. MMWR. 2015; 64: 699–702.
Baxter R, Tran TN, Ray P, Lewis E, Fireman B, Black S et al. Impact of vaccination on the epidemiology of varicella: 1995–2009. Pediatrics. 2014; 134 (1): 24–30.
Leung J, Harpaz R. Impact of the Maturing Varicella Vaccination Program on Varicella and Related Outcomes in the United States: 1994–2012. J Pediatric Infect Dis Soc. 2015 (doi:10.1093/jpids/piv044).
Lau WC, Murray M, El-Turki A, Saxena S, Ladhani S, Long P, et al. Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom. Vaccine. 2015; 33 (39): 5072–5079.
Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015; 15 (3): 301–309.
Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its intro¬duction: an observational cohort study. Lancet Infect Dis. 2015; 15 (5): 535–543.
Sadarangani M, Scheifele DW, Halperin SA, Vaudry W, Le Saux N, Tsang R, et al. The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012. Clin Infect Dis. 2014; 59 (9): 1208–1215.
Haller S, Dehnert M, Karagiannis I, Rieck T, Siffczyk C, Wichmann O, et al. Effectiveness of routine and booster pertussis vaccination in children and adolescents, federal state of Brandenburg, Germany, 2002–2012. Pediatr Infect Dis J. 2015; 34 (5): 513–519.
Acosta AM, DeBolt C, Tasslimi A, Lewis M, Stewart LK, Misegades LK, et al. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. Pediatrics. 2015; 135 (6): 981–989.
Ciszewski A. Komentarz. W: Szczepienie przeciwko grypie a ryzyko zgo¬nu z przyczyn sercowo-naczyniowych u chorych na chorobę wieńcową – przegląd systematyczny z metaanalizą. Med Prakt. 2015; 9: 112–115.
Siriwardena AN, Asghar Z, Coupland CC. Influenza and pneumococcal vaccination and risk of stroke or transient ischaemic attack-matched case control study. Vaccine. 2014; 32 (12): 1354–1361.
Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. Clin Infect Dis. 2015; 60 (5): e11–9.
Payne DC, Baggs J, Zerr DM, Klein NP, Yih K, Glanz J, et al. Protective association between rotavirus vaccination and childhood seizures in the year following vaccination in US children. Clin Infect Dis. 2014; 58(2): 173–177.
Karafillakis E, Hassounah S, Atchison C. Effectiveness and impact of rotavirus vaccines in Europe, 2006–2014. Vaccine. 2015; 33 (18): 2097–107.
Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ. 2014; 349: g4643 (doi: 10.1136/bmj.g4643).
Gara N, Abdalla A, Rivera E, Zhao X, Werner JM, Liang TJ, et al. Durability of antibody response against hepatitis B virus in healthcare workers vaccinated as adults. Clin Infect Dis. 2015; 60 (4): 505–513.
Raczniak GA, Bulkow LR, Bruce MG, Zanis CL, Baum RL, Snowball MM, et al. Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series. J Infect Dis. 2013; 207 (3): 493–496.
Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, doublblind PATRICIA trial. Clin Vaccine Immunol. 2015; 22(4): 361–373.
Bernatowska E. Bezpieczeństwo szczepień ochronnych. Polskie Towarzystwo Wakcynologii. 42543.
Abrams JY, Weintraub ES, Baggs JM, McCarthy NL, Schonberger LB, Lee GM, et al. Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996–2006. Vaccine. 2015; 33(2): 382–387.
Mrukowicz J. Czy szczepionki zawierają toksyczne składniki? http:// show.html109630.
Klein NP, Lewis E, Fireman B, Hambidge SJ, Naleway A, Nelson JC, et al. Safety of measles-containing vaccines in 1-year-old children. Pediatrics. 2015; 135 (2): 321–329.
Uno Y, Uchiyama T, Kurosawa M, Aleksic B, Ozaki N. Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder. Vaccine. 2015; 33(21): 2511–2516.
Sun Y, Christensen J, Hviid A, Li J, Vedsted P, Olsen J, et al. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B. JAMA. 2012; 307(8): 823–831.